Isentress Clinical Trials Isentress RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Effect on Liver Fat and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Raltegravir
Conditions:   HIV Seropositivity;   Metabolic Syndrome;   Fatty Liver Intervention:   Drug: Raltegravir Sponsors:   Helsinki University Central Hospital;   Merck Sharp & Dohme Corp. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 15, 2017 Category: Research Source Type: clinical trials